IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT [IDS]

Honorable Commissioner for Patents U.S. Patent and Trademark Office Randolph Building, Mail Stop Amendments 401 Dulany Street Alexandria, VA 22314

Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

- [X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:
- [] A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above-identified international application.

[XX]B. before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114; or

the property of the second

- [X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached, except as explained below:
- [X] A. Document \underline{AN} is deemed substantially cumulative to document \underline{AO} , and, in accordance with 37 CFR §1.98(c), a copy of each of the former document(s) is not enclosed.
 - [X] 3. Document(s) AA-AM are not in the English language. In accordance with 37 CFR §1.98(a)(3), Applicant states:
 - [X] An English translation of each document AA-AM (or of the pertinent portions thereof), or a copy of an English-language abstract (or claim) is enclosed.
- [X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).
- 5. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the

In re Appln. No. 10/553,695

face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Respectfully submitted,

BROWDY AND NEIMARK

Attorneys for Applicant(s)

By:

Sheridan Neimark

Registration No. 20,520

SN:dac

624 Ninth Street, N.W., Suite 300

Washington, D.C. 20001-5303

Telephone: (202)628-5197 Facsimile: (202)737-3528

 $G:\BN\S\siks\Kumazawa1\pto\2006-08-07$ ids.fee.doc

Substitute f	Substitute for form 1449A/PTO			Complete if Known			
				Application Number	10/553,695		
INFORMATION DISCLOSURE				Filing Date	February 21, 2005		
STAT	STATEMENT BY APPLICANT			First Named Inventor	Yoshio KUMAZAWA		
•				Group Art Unit			
	(use as many sheets	as n	ecessary)	Examiner Name			
Sheet	1	of	3	Attorney Docket Number	KUMAZAWA1		

			U.S. PAT	ENT DOCUMENTS	
		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Examiner Initials*	Cite No.1	Number-Kind Code ^{2 (if known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
		US-		¨	
		US-			
		US-			
		US-			
	l	US-			
		US-			
		US-			
		US-	1		
		US-			

		FOREIG	ON PATENT DO	CUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
	AA	JP06-145189A	05-24-1994	Kitasato Inst		
	AB	JP2002-10797A	01-15-2002	Kibun Food Chemifa Co Ltd		
	AC	JP11-43437A	02-16-1999	Kibun Food Chemifa Co Ltd.		
	AD	JP2000-51676A	2-22-2000	Kibun Food Chemifa Co Ltd.		
	AE	JP2002-097152A	04-02-2002	Rikomu:KK		
	AF	JP2002-265366A	09-18-2002	Takeda Food Products Ltd.		
	AG	JP2001-031585A	02-06-2001	Nagase & Co Ltd		
	AH	JP2003-146887A	05-21-2003	Gotoo Corporation:KK		
	AI	JP09-315980A	12-09-1997	Kirin Brewery Co Ltd		
	AJ	JP2003-199587A	07-15-2003	Mitsubishi Chemicals Corp		
	AK	WO 03/030938 A1	04-17-2003	Orient Cancer Therapy Co	<u> </u>	
	AL	WO 01/82935 A1	11-08-2001	Orient Cancer Therapy Co		

Examiner	Date	
Signature	 Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				Complete if Known		
				Application Number	10/553,695	
INFORMATION DISCLOSURE				Filing Date	February 21, 2005	
STAT	STATEMENT BY APPLICANT			First Named Inventor	Yoshio Kumazawa	
				Group Art Unit		
	(use as many sheet	s as n	ecessary)	Examiner Name		
Sheet	2	of	3	Attorney Docket Number	KUMAZAWA1	

			U.S. PAT	ENT DOCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-	_		
		US-		-	100
		US-			
		US-			
		US-		, , <u>, , , , , , , , , , , , , , , , , </u>	
		US-			
		US-			
		US-			
-		US-			
		US-			
		US-			

		FOREIC	ON PATENT DO	CUMENTS		
Examiner	0110	Foreign Patent Number Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	of Cited Document	Pages, Columns, Lines, Where Relevant Passages or	T ⁶
Initials*	No.1			or choc a coamon.	Relevant Figures Appear	T
_	AM	WO 98/44928	10-15-1998	Kirin Brewery		
A A	AN	JP2002-509861A1	04-02-2002	Cohen et al.		
- 7	AO	WO 99/43814	09-02-1999	Cohen et al.		
				-		
					, , , , , , , , , , , , , , , , , , , ,	
		<u> </u>		<u> </u>		

Examiner	Date	···
Signature	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form	1449A/PTO	<u>-</u>	Complete if Known		
			Application Number	10/553,695	
INFORM	ATION DISC	CLOSURE	Filing Date	February 21, 2005	
STATEM	ENT BY AP	PLICANT	First Named Inventor	Yoshio KUMAZAWA	
· · · · · · · · · · · · · · · · · · ·			Group Art Unit		
(use	as many sheets as n	ecessary)	Examiner Name		
Sheet 3	of	3	Attorney Docket Number	KUMAZAWA1	

NON PATENT LITERATURE DOCUMENTS / OTHER INFORMATION					
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²		
	AP	C. KRZIWON et al., Glycospingolipids from Sphingomonas paulcimobilis Induce Monokine Production in Human Mononuclear Cells; Infection and Immunity, Aug 1995, pp. 2899-2905, Vol. 63, No 8			
	AQ	D. WU et al., Bacterial glycolipids and analogs as antigens for CD1d-restricted NKT cells; PNAS, February 1, 2005, Vol. 102, No. 5, pp. 1351-1356			

Examiner	Date	
Signature	Considered	

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.